Restem

Executive Summary

Restem is a clinical-stage biotechnology company developing off-the-shelf, cell-based therapeutics for inflammatory and age-related diseases. Founded in 2015 and headquartered in San Diego, the company leverages proprietary platforms to modulate the immune system. Restem is currently advancing its lead candidate through Phase 2/3 clinical trials, positioning itself as a potential leader in allogeneic cell therapy. While private and without disclosed financing, Restem's focus on scalable, off-the-shelf products addresses key limitations of autologous cell therapies, offering advantages in cost and patient access. The company's upcoming milestones include pivotal data readouts and potential strategic collaborations, which could drive significant value inflection.

Upcoming Catalysts (preview)

• Q4 2026Phase 2/3 Clinical Trial Data Readout60% success
• Q2 2026Series C Financing Round75% success
• Q3 2026Strategic Partnership or Licensing Deal50% success